pSivida (NASDAQ:PSDV) has appointed Nancy Lurker as president, CEO and a member of the board, succeeding Paul Ashton, who has resigned to pursue other interests.
Ms. Lurker, a seasoned healthcare executive, brings strong leadership and extensive experience in maximizing the potential of new therapies and successfully implementing innovative U.S. and global drug launches. From 2008 to 2015, she served as president, CEO and a director of PDI.
“As we move toward the submission of U.S. and EU marketing approval applications for Medidur, this is an ideal time to bring on the skill set and experience Nancy possesses,” David Mazzo, chairman of pSivida, said in a statement.
“Nancy’s significant experience in building high performing teams, strategic leadership and extensive product commercialization will help us move pSivida to its next stage of development and success,” he added.
